The new agreement will provide Lonza with access to Arbor’s gene editing technology

Read more:
Arbor Biotechnologies and Lonza Enter into Gene Editing Technology Licensing Deal

Follow this link:
Bespoke Extracts Welcomes Mixed Martial Artists Paige VanZant and Austin Vanderford to the Growing Team of Bespoke CBD Brand Ambassadors

TORONTO, Dec. 23, 2020 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company developing new drug candidates for treating organ damage caused by inflammation, today announced it has arranged a non-brokered private placement offering of 430,000 common shares priced at $1.50 per common share (the “Common Shares”) for gross proceeds of $500,000 USD (approximately $645,000 CAD) (the “Offering”).

Continue reading here:
Arch Biopartners Arranges Non-Brokered Private Placement

TORONTO, Dec. 23, 2020 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce an update on the Company’s U.S. Food & Drug Administration (“FDA”) Phase 3 clinical trial (the “Study”) to evaluate the safety and efficacy of Bucillamine in patients with mild to moderate COVID-19. The Company is on pace to meet its enrollment goals for the Independent Data and Safety Monitoring Board (“DSMB”) to review the safety and efficacy data from the 210 patients as part of the first interim analysis of patients treated and followed up for 28 days after randomization.

Link:
Revive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19 with Plans on Emergency Use Access

Hamilton, MT Facility Is Planned to Manufacture Vaccines at Commercial Scale, Including Vaccines Under Development for COVID-19

Visit link:
Tonix Pharmaceuticals Plans Commercial Scale Vaccine Manufacturing Facility

MONMOUTH JUNCTION, N.J., Dec. 23, 2020 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a?late clinical-stage?biopharmaceutical company?working to develop the first FDA-approved ophthalmic formulation of bevacizumab-vikg?for use in retinal?indications, today announced its corporate highlights and financial results for its fiscal year ended September 30, 2020.

See the rest here:
Outlook Therapeutics Reports Financial Results for Fiscal Year 2020 and Provides Corporate Update

More:
Tauriga Sciences Inc. to Expand its Existing Product Line of CBD Infused Bath Bombs, Branded Under the Tauri-Gum Name

Business combination transaction with LifeSci Acquisition Corp. was completed on December 23, 2020

See original here:
Vincera Pharma Announces Completion of Business Combination and Listing on Nasdaq

Will Trade on the Nasdaq Global Market Under Ticker “GBS” Will Trade on the Nasdaq Global Market Under Ticker “GBS”

See more here:
UPDATE - GBS Inc. Announces Pricing of $21.6 Million Initial Public Offering

SOUTH SAN FRANCISCO, Calif., Dec. 23, 2020 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer today announced that the U.S. Food & Drug Administration (FDA) has cleared an Investigational New Drug (IND) application to study ALLO-715, Allogene’s investigational BCMA AlloCAR T therapy, in combination with nirogacestat, SpringWorks Therapeutics’ investigational gamma secretase inhibitor (GSI), in patients with relapsed or refractory multiple myeloma. This combination is part of the company’s multi-pronged strategy to develop a treatment for multiple myeloma and will be deployed in the ongoing UNIVERSAL trial. Enrollment in this cohort is expected to begin in the first quarter of 2021.

See more here:
Allogene Therapeutics Receives IND Clearance from the U.S. Food and Drug Administration for ALLO-715 in Combination with Nirogacestat in...

Mechelen, Belgium; 23 December 2020, 18.00 CET – Galapagos NV (Euronext & NASDAQ: GLPG) today announces that Onno van de Stolpe, CEO of Galapagos, has committed to make a personal €10 million donation to African Parks, a non-profit organization that serves at the front lines of wildlife conservation, ecosystem restoration, and community development. The €10 million donation will be in the form of ordinary shares of Galapagos, donated by Mr. van de Stolpe to African Parks and spread over the coming five years. The first €2 million (25,150 ordinary shares held by Mr. van de Stolpe) have been transferred on 22 December 2020.

See the article here:
Galapagos’ CEO makes donation of €10 million in the form of personal shares to African Parks

LAVAL, Québec, Dec. 23, 2020 (GLOBE NEWSWIRE) -- At the request of IIROC, Acasti Pharma Inc. (“Acasti or the “Company”) (NASDAQ: ACST – TSX-V: ACST) wishes to confirm that the Company’s management and Board of Directors are unaware of any material change in the Company’s operations that would account for the recent increase in market activity.

Visit link:
Acasti Pharma Unaware of Any Material Change

GAITHERSBURG, Md., Dec. 23, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has issued a clinical hold on the Company’s Investigational New Drug (IND) application for AdCOVID, a single-dose intranasal COVID-19 vaccine candidate. The Agency requested certain protocol modifications and the submission of additional Chemistry, Manufacturing and Controls (CMC) data. Altimmune has responded to the Agency’s clinical hold letter received on December 22, 2020 and, at this time, does not anticipate a significant impact on the overall clinical development timeline as the Company has agreed to each of the FDA’s requests.

Excerpt from:
Altimmune Provides an Update on its Investigational New Drug Application for a Phase 1 AdCOVID™ Clinical Trial

WEST CHESTER, Pa., Dec. 23, 2020 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that it has resubmitted the New Drug Application (NDA) for VP-102 for the treatment of molluscum contagiosum (molluscum) to the U.S. Food and Drug Administration (FDA). The NDA for VP-102 was resubmitted based on the outcome and final minutes of a Type A meeting with the FDA, which was conducted to obtain clarity on the Complete Response Letter (CRL) issued by the FDA in July 2020.

Continued here:
Verrica Pharmaceuticals Announces Resubmission of New Drug Application for VP-102 for the Treatment of Molluscum Contagiosum

PLEASANTON, Calif., Dec. 23, 2020 (GLOBE NEWSWIRE) -- 10x Genomics (Nasdaq: TXG) today announced the company will be participating in the upcoming 39th Annual J.P. Morgan Virtual Healthcare Conference.

The rest is here:
10x Genomics to Present at the 39th Annual J.P. Morgan Healthcare Conference

VANCOUVER, British Columbia, Dec. 23, 2020 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (“Novelion” or the “Company”) by Alvarez & Marsal Canada Inc., Novelion’s court appointed liquidator (the “Liquidator”) today announces its intention to make an interim distribution to its registered shareholders in January 2021 (the “Interim Distribution”). The Interim Distribution will be made pursuant to an Order of the Supreme Court of British Columbia (the “Court”) dated December 16, 2020 in accordance with the Company’s Liquidation Plan. The mechanics of the Interim Distribution are in the process of being finalized and the date of the Interim Distribution will be communicated to the Company’s shareholders by way of a subsequent press release once confirmed.

See original here:
Novelion Announces Court Approval for Interim Distribution to Registered Shareholders

Leading experts to evaluate the clinical and regulatory path to approval in the US market of COVAXIN™, a whole-virion inactivated COVID-19 vaccine Leading experts to evaluate the clinical and regulatory path to approval in the US market of COVAXIN™, a whole-virion inactivated COVID-19 vaccine

Read the original post:
Ocugen Establishes Vaccine Scientific Advisory Board

PRESS RELEASE – REGULATED INFORMATION

Follow this link:
Bone Therapeutics SA: Transparency notification received from CPH Banque

BOGOTÁ, Colombia, Dec. 24, 2020 (GLOBE NEWSWIRE) -- Medcolcanna Organics Inc. (“Medcolcanna”, “MCCN” or the “Company”) (NEO: MCCN), a leading Colombian and globally integrated cannabis company, is pleased to announce that it has closed on the second and final tranche of its previously announced offering of convertible debentures as per the press release dated August 28, 2020, raising gross aggregate proceeds of $0.25 million, bringing the total amount raised pursuant to this offering to $1.25 million, being the full amount previously disclosed. The offering consists of convertible secured debentures (the “Debentures”). The Debentures are convertible into common shares in the capital of the Company (“Common Shares”) on the following terms: the Debentures are issuable in $1,000 increments and are convertible into Common Shares at a price of $0.20 per share (meaning 5,000 shares may be issued on the conversion of each Debenture) and will have a term of two (2) years from the date of issuance, with interest payable twice yearly of fourteen percent (14%) per annum (simple not compounded), payable in cash or shares. The Debentures will be subject to earlier redemption by the Company in the event the Common Shares are trading on the facilities of the Neo Exchange Inc. (or such other stock exchange on which the Common Shares may then be trading) at a volume weighted average trading price at or above $0.40 per share for a period of not less than ten (10) consecutive trading days.

Here is the original post:
Medcolcanna Organics Inc. Announces Closing of Upsized Convertible Debenture Financing

The Company has Now Resumed the Clinical Development of its Proposed Anti-Nausea Pharmaceutical Grade Version of Tauri-Gum™

Link:
Tauriga Sciences Inc. Funds the Entirety of the Master Services Agreement that it Recently Entered Into with CSTI